David R Beers
Overview
Explore the profile of David R Beers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
3728
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thonhoff J, Beers D, Zhao W, Faridar A, Thome A, Wen S, et al.
Front Neurol
. 2024 Jun;
15:1415106.
PMID: 38915796
Objective: To determine whether a combination therapy with abatacept (CTLA4-Ig) and interleukin-2 (IL-2) is safe and suppresses markers of oxidative stress, inflammation, and degeneration in ALS. Methods: In this open-label...
2.
Faridar A, Eid A, Thome A, Zhao W, Beers D, Pascual M, et al.
Transl Neurodegener
. 2023 Nov;
12(1):54.
PMID: 37968718
Trial Registration: ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic. Clinicaltrials: gov/ct2/show/NCT05821153.
3.
Faridar A, Vasquez M, Thome A, Yin Z, Xuan H, Wang J, et al.
Acta Neuropathol Commun
. 2022 Sep;
10(1):144.
PMID: 36180898
Background: Regulatory T cells (Tregs) play a neuroprotective role by suppressing microglia and macrophage-mediated inflammation and modulating adaptive immune reactions. We previously documented that Treg immunomodulatory mechanisms are compromised in...
4.
Thonhoff J, Berry J, Macklin E, Beers D, Mendoza P, Zhao W, et al.
Neurol Neuroimmunol Neuroinflamm
. 2022 Aug;
9(6).
PMID: 36038262
Background And Objectives: In a phase 1 amyotrophic lateral sclerosis (ALS) study, autologous infusions of expanded regulatory T-lymphocytes (Tregs) combined with subcutaneous interleukin (IL)-2 were safe and well tolerated. Treg...
5.
Thome A, Thonhoff J, Zhao W, Faridar A, Wang J, Beers D, et al.
Front Immunol
. 2022 Jul;
13:875825.
PMID: 35812435
Extracellular vehicles (EVs) are efficient biomarkers of disease and participate in disease pathogenesis; however, their use as clinical therapies to modify disease outcomes remains to be determined. Cell-based immune therapies,...
6.
Beers D, Thonhoff J, Faridar A, Thome A, Zhao W, Wen S, et al.
Ann Neurol
. 2022 Apr;
92(2):195-200.
PMID: 35445431
Oxidative stress (OS) induces inflammation, which in turn exacerbates OS and the expression of acute phase proteins (APPs). Regulatory T lymphocyte (Treg) therapy was assessed for suppression of OS and...
7.
Beers D, Zhao W, Thonhoff J, Faridar A, Thome A, Wen S, et al.
Brain Behav Immun Health
. 2021 Sep;
12:100209.
PMID: 34589734
Amyotrophic lateral sclerosis (ALS) is a multifactorial, multisystem pro-inflammatory neuromuscular disorder. Activation of programmed cell death-1 (PD-1), and its ligands, programmed cell death-ligand 1 and 2 (PD-L1/L2), leads to immune...
8.
Appel S, Beers D, Zhao W
Curr Opin Neurol
. 2021 Aug;
34(5):765-772.
PMID: 34402459
Purpose Of Review: Neuroinflammation is an important mediator of the pathogenesis of disease in amyotrophic lateral sclerosis (ALS). Genetic mutations such as C9orf72 have begun to define the numerous cell...
9.
Thome A, Atassi F, Wang J, Faridar A, Zhao W, Thonhoff J, et al.
NPJ Parkinsons Dis
. 2021 May;
7(1):41.
PMID: 33986285
Inflammation is a pathological hallmark of Parkinson's disease (PD). Chronic pro-inflammatory responses contribute to the loss of neurons in the neurodegenerative process. The present study was undertaken to define the...
10.
Faridar A, Thome A, Zhao W, Thonhoff J, Beers D, Pascual B, et al.
Brain Commun
. 2020 Sep;
2(2):fcaa112.
PMID: 32954348
Inflammation is a significant component of Alzheimer's disease pathology. While neuroprotective microglia are important for containment/clearance of Amyloid plaques and maintaining neuronal survival, Alzheimer inflammatory microglia may play a detrimental...